|
市場調查報告書
中國醫藥業：策略、動向、市場機會
Chinese Pharmaceutical Industry: Strategies, Trends and Opportunities
|
本報告已在2011年07月19日停止出版。
中國醫藥業在高齡人口增加與政府的扶植政策下持續擴大，預料 2010 年將成為全球第 5 大市場。
專營軟體相關諮詢服務的印度市調公司 Digital Vector, Inc.（總公司：班加洛），調查分析了中國醫藥業後，出版了一本綜合報告書 "Chinese Pharmaceutical Industry: Strategies, Trends and Opportunities"。
報告書內容包括：業界概況、各市場部門現況、課題分析、藥物與醫療保險制度相關政策、未來策略與預測等等，內容綱要摘記如下：
業界概要
主要動向
業界變化
- 法律規範
- 研發投資、研發外部化
- 生產
- 流通
- 出口
- 國際合作
政府政策
- 藥物定價相關政策
- 市場自由化
- 法律規範框架
- 獎勵金制度
- 市場合理化
社會與經濟面課題
- 中國商業網路
- 商談
- 政治制度
- 法律制度
- 總體經濟環境
- 技術環境
生技業界
醫療系統
- 主要趨勢
- 過去事例
- 醫療系統的變化
- 醫療系統的結構
- 關鍵角色
- 醫院
- 外資
- 農村地區醫療
- 都市醫療
- 人才
- 政府優先事項
- 中國醫療改革
- 醫療政策
- 建議
- 財務面改革
- 醫療保險制度
醫療設備市場
- 銷售額較高的產品群
- 市場力學
- 國際定位
- 競爭
- 市場研發機會
- 市場規範當局之角色
- 課題
- 成功策略
醫療保險市場
- WTO 的影響
- 法律規範
- 保險業規範的寬鬆
- 國內企業與外資企業
- 市場潛力
- 醫療保險市場（都市與鄉村）
- 課題
藥價制度改革與政策
一般藥物市場
臨床實驗市場
- 地區臨床實驗市場的要求事項
- 臨床實驗相關法規
- 臨床實驗與 CRO（研發業務受託機構）
- 中國企業的優勢
- 外商企業的優勢
- 課題
- 建議
藥物流通
新藥物相關法規
- 新藥物相關法規歷史
- 新藥物區分
- 許可流程
- 新藥物行銷的排他性要求事項
知識財產權保護
- 中國知識財產權保護
- 知識財產權保護的制度變更
- 中國專利事務所採用
- 其他
中藥
未來預測
未來策略
ABSTRACT
China is expected to become the fifth largest drug market in the world by 2010. Growth will be driven by factors such as an increasingly ageing population, large market size (urban and rural), government support in restructuring the highly fragmented industry, IPR policies, as well as increasing life expectancy.
China will remain an attractive location to foreign drug companies, because China offers many advantages in terms of the size of its marketplace, the relatively easy access to patients who are available for clinical trials, and lower clinical trial costs.
China has made considerable progress towards an improved standard of living for its population, including better health, reduced levels of poverty, and strong macroeconomic growth. The market for high quality, patient-oriented healthcare services is small, but growing steadily. Most Chinese lack health insurance and only a fraction of the population can afford top-end Western medical care. Currently, there are many successful foreign and joint venture healthcare service providers already in China. Their experiences point to growing opportunities for foreign companies looking to invest in this segment of the market. TABLE OF CONTENTS
INDUSTRY GROWTH
- INDUSTRY GROWTH
- PHARMACEUTICAL MARKET
- POTENTIAL
- DRIVERS OF CHINESE
- PHARMACEUTICAL INDUSTRY
- INDUSTRY CHARACTERISTICS
- DOMESTIC INDUSTRY
- DISEASE PROFILE
- DRUGS WITH LARGEST MARKET
- SCOPE
- PRODUCT STRATEGIES
KEY TRENDS
- INDUSTRY CHALLENGES
- IMPACT OF WTO MEMBERSHIP
- INDUSTRY CONSOLIDATION
- ROLE OF GOVERNMENT
- IMPORTS VS. EXPORTS
- INCENTIVE STRUCTURES
INDUSTRY IN TRANSITION
- REGULATIONS
- R&D INVESTMENTS
- R&D EXTERNALISATION
- MANUFACTURING
- DISTRIBUTION
- EXPORTS
- COLLABORATION WITH
- MULTINATIONALS
- ADVANTAGES FOR CHINESE ENTITIES
- ADVANTAGES FOR MULTINATIONALS
- MULTINATIONAL MANUFACTURING
- FACILITIES
- INTERACTIONS WITH US FDA
- CHALLENGES
- FUTURE OUTLOOK POST-REFORM
GOVERNMENT POLICIES
- PHARMACEUTICAL PRICING POLICY
- DRUG PRICING REFORMS PRICING OF DRUGS PROFIT MARGINS
- MARKET LIBERALISATION REGULATORY FRAMEWORKS INCENTIVES
- RATIONALISATION OF MARKET SFDA CLASSIFICATION
SOCIAL AND CULTURAL ISSUES
- CHINESE BUSINESS NETWORKS NEGOTIATION
- THE POLITICAL SYSTEM THE LEGAL SYSTEM
- MACRO ECONOMIC ENVIRONMENT TECHNOLOGICAL ENVIRONMENT
BIOTECHNOLOGY INDUSTRY
- GOVERNMENT ROLE RESEARCH INITIATIVES CHALLENGES
CHINESE HEALTHCARE SYSTEM
- KEY TRENDS IN HEALTHCARE
- MAJOR DISEASES
- DISEASE PREVENTION MECHANISMS
- PAST EXPERIENCES
- HEALTH CARE DELIVERY NETWORK EVOLVING HEALTH CARE DELIVERY NETWORK
- HEALTHCARE SYSTEM CHANGES STRUCTURE OF CHINA S HEALTHCARE SYSTEM
- HEALTHCARE FINANCING
- REGULATIONS
- KEY PLAYERS IN THE CHINESE HEALTHCARE SYSTEM
- HOSPITALS
- STATE-OWNED HOSPITALS HOSPITAL FUNDING
- FOREIGN INVESTORS IN CHINESE HEALTHCARE
- JOINT VENTURES
- LESSONS FROM THE PAST CHALLENGES FOR FOREIGN INVESTORS
- POLICY RECOMMENDATIONS
- RURAL HEALTHCARE
- URBAN HEALTHCARE HEALTHCARE PERSONNEL GOVERNMENTAL PRIORITIES IN HEALTHCARE
- HEALTHCARE REFORMS IN CHINA HEALTHCARE POLICY
- RECOMMENDATIONS
- HEALTHCARE FINANCING REFORMS
- NATIONAL ESSENTIAL DRUG LIST (NEDL)
- HEALTHCARE INSURANCE IN CHINA
- CHARACTERISTICS
- HEALTHCARE INSURANCE REFORMS
MEDICAL EQUIPMENTS AND DEVICES MARKET
- TOP SELLING PRODUCT CATEGORIES MARKET DYNAMICS
- MULTINATIONAL PRESENCE COMPETITION
- KEY MARKET CHARACTERISTICS OPPORTUNITIES TO EXPLOIT MARKET REGULATORS AND THEIR ROLES
- CHALLENGES
- STRATEGIES FOR SUCCESS
CHINA S MEDICAL INSURANCE MARKET
- IMPACT OF WTO
- INSURANCE REGULATIONS IN CHINA LIBERALISATION OF INSURANCE INDUSTRY
- DOMESTIC AND FOREIGN INSURANCE COMPANIES
- RECOMMENDATIONS
- POTENTIAL FOR INSURANCE MARKET IN CHINA
- URBAN MEDICAL INSURANCE RURAL MARKET FOR MEDICAL INSURANCE
- INDUSTRY CHALLENGES FUTURE DIRECTIONS
CHINA S DRUG PRICING REFORM AND DRUG PRICING POLICY
- CHALLENGES IN THE CHINESE DRUG PRICING SYSTEM
- CHINA S DRUG PRICING REFORMS FUTURE OF CHINA S DRUG PRICING REFORMS
CHINA S OTC DRUG MARKET
- FOREIGN ENTRANTS REGIONAL VARIATIONS RETAIL MARKET
- COSMETICS MARKET
CLINICAL TRIALS MARKET
- CLINICAL TRIAL REQUIREMNETS FOR THE LOCAL MARKET
- CLINICAL TRIAL REGULATIONS CLINICAL TRIALS AND CONTRACT RESEARCH ORGANIZATIONS IN CHINA BENEFITS FOR CHINESE INDUSTRY BENEFITS FOR FOREIGN PLAYERS CHALLENGES
- RECOMMENDATIONS
PHARMACEUTICAL DISTRIBUTION IN CHINA
- STATE CONTROL OF DISTRIBUTION CHANNELS
REGULATORY ISSUES FOR NEW DRUGS IN CHINA
- HISTORY OF NEW DRUG REGULATION IN CHINA
- CLASSIFICATION OF NEW DRUGS IN CHINA
- DRUG REVIEW PROCESS
- NEW DRUG REVIEW TIME
- NEW DRUG MARKETING EXCLUSIVITY CLINICAL REQUIREMENTS
- IMPORTED DRUGS
- CLASS 1 NCE REGISTRATION
INTELLECTUAL PROPERTY PROTECTION ISSUES
- INTELLECTUAL PROPERTY PROTECTION IN CHINA ADMINISTRATIVE PROTECTION CHANGING IP PROTECTION REGIME ADAPTATION OF CHINESE FIRMS
TRADITIONAL CHINESE MEDICINE
- POPULARITY OF TRADITIONAL CHINESE MEDICINE (TCM) IN CHINA FORMS OF TCM
- TCM DRIVING THE HEALTH FOOD INDUSTRY
- POPULARITY OF TCM OUTSIDE OF CHINA
- GLOBAL SCOPE FOR CHINESE TCM
FORECASTS FOR THE FUTURE
STRATEGIES FOR THE FUTURE
- STRATEGIC OPTIONS FOR CHINESE FIRMS
- GENERICS
- TRADITIONAL MEDICINE NCEs RESEARCH
- SUPPORT FOR NEW ENTERPRISES GOVERNMENT POLICIES
LIST OF TABLES
- Table 1: Leading Chinese Provinces By Pharmaceutical Sales
- Table 2: Drugs With Largest Market Scope
- Table 3: Fastest Growing Therapeutic Categories
- Table 4: Registration Procedure For Pharmaceutical Imports
- Table 5: Foreign Invested Pharmaceutical Firms
- Table 6: Collaboration Between Chinese Firms And Foreign Mncs
- Table 7: Government-Set Profit Margins For Drug Types In China
- Table 8: Death Rate Of Major Diseases In Urban Areas
- Table 9: Death Rate Of Major Diseases In Rural
- Table 10: Percentage Of Children Vaccinated For Various Diseases
- Table 11: Foreign Insurance Companies In China
- Table 12: Leading Pharmaceutical Categories In China s Retail Market
- Table 13: Leading Imported Pharmaceutical Categories In China s Retail Market Table
- 14: Leading Pharmaceutical Manufacturers In China s Retail Market Table
- 15: Leading Pharmaceutical Products In China s Retail Market By Sales Table
- 16: Leading Pharmaceutical Categories In China s Retail Market By Volume
TABLE OF FIGURES
- Figure 1: Size Of Chinese Pharmaceutical & Biotechnology Industry
- Figure 2: Break-Up Of Chinese Pharmaceutical Firms Based On Ownership Structure
- Figure 3: Break-Up Of Chinese Pharmaceutical Firms Based On Output
- Figure 4: Break-Up Of Chinese Pharmaceutical Firms Based On Output
- Figure 5: Break-Up Of China s Drug Market Profile
- Figure 6: Projected Break-Up Of China s Drug Market Profile In 2010
- Figure 7: Size Of China s Pharmaceutical Exports
- Figure 8: Chinese Political System
- Figure 9: Number Of Biotechnology Companies In China
- Figure 10: Sales Of Biotechnology Products In China
- Figure 11: Biotechnology Patents Granted In China
- Figure 12: Mapping Of The Chinese Government Network In Healthcare
- Figure 13: Chinese Healthcare Expenditure
- Figure 14: Healthcare Expenditure As A % Of Gnp
- Figure 15: Chinese Healthcare Network
- Figure 16: Size Of China s Medical Equipment Market
- Figure 17: Insurance Premium Growth In China
- Figure 18: Density Of Life Insurance In China
- Figure 19: Penetration Of Life Insurance In China
- Figure 20: OTC Pharmaceutical Sales In China
- Figure 21: Retail Pharmaceutical Outlets In China
- Figure 22: China s Otc Drug Distribution Pattern
- Figure 23: China Drug Distribution Network
|
